Overview

Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)

Status:
Completed
Trial end date:
2021-04-26
Target enrollment:
Participant gender:
Summary
The objective of this proposed study is to investigate the pharmacokinetics interaction between CHF6001 as substrate and Itraconazole as inhibitor of CYP3A4/5 in a drug-drug interaction study.
Phase:
Phase 1
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Treatments:
Itraconazole